Unknown

Dataset Information

0

Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).


ABSTRACT: Minimal residual disease (MRD) after initial therapy is integral to risk stratification in B-precursor and T-precursor acute lymphoblastic leukemia (B-ALL, T-ALL). Although MRD determines depth of remission, remission remains defined by morphology. We determined the outcomes of children with discordant assessments of remission by morphology vs. flow cytometry using patients age 1-30.99 years enrolled on Children's Oncology Group ALL trials who underwent bone marrow assessment at the end of induction (N?=?9350). Morphologic response was assessed locally as M1 (<5% lymphoblasts; remission), M2 (5-25%), or M3 (>25%). MRD was centrally measured by flow cytometry. Overall, 19.8% of patients with M2/M3 morphology had MRD?

SUBMITTER: Gupta S 

PROVIDER: S-EPMC5992047 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


Minimal residual disease (MRD) after initial therapy is integral to risk stratification in B-precursor and T-precursor acute lymphoblastic leukemia (B-ALL, T-ALL). Although MRD determines depth of remission, remission remains defined by morphology. We determined the outcomes of children with discordant assessments of remission by morphology vs. flow cytometry using patients age 1-30.99 years enrolled on Children's Oncology Group ALL trials who underwent bone marrow assessment at the end of induc  ...[more]

Similar Datasets

| S-EPMC7594384 | biostudies-literature
| S-EPMC4701208 | biostudies-literature
| S-EPMC1895482 | biostudies-literature
| S-EPMC9237978 | biostudies-literature
| S-EPMC2717759 | biostudies-literature
| S-EPMC7280050 | biostudies-literature
| S-EPMC4300959 | biostudies-literature
| S-EPMC3731070 | biostudies-literature
| S-EPMC3175785 | biostudies-literature